Posts

Posted on

Arconic Announces Austin Camporin Will Step Down from the Board

Arconic Announces Austin Camporin Will Step Down from the Board

PITTSBURGH–(BUSINESS WIRE)–
Arconic Corporation (NYSE: ARNC) (“Arconic”) announced today that Austin G. Camporin will be stepping down from the Board of Directors effective December 10th.

Mr. Camporin, Portfolio Manager at Elliott Management, has served on the Arconic Board and its Finance Committee since its launch as a standalone company on April 1, 2020.

“We want to thank Austin for his service to the Board at such a foundational stage of the company,” said Frederick “Fritz” Henderson, Chairman of the Board. “His insights and unique experience provided value to Arconic’s Board and management team.”

Mr. Camporin commented that “Arconic is a tremendous company and has been a strong long-term investment for Elliott Management. I am proud to have served as a director during its successful launch and to have played a role in setting a course for the company to continue to thrive and grow. Arconic today is well positioned to execute on numerous opportunities before it to drive operational efficiency, improved capacity utilization and increased market share, all thanks to the company’s great leadership team and its talented employees. I want to commend Tim, Fritz, and the entire management team and board for such a positive, collaborative experience. I look forward to Arconic’s continued success.”

About Arconic

Arconic Corporation (NYSE: ARNC), headquartered in Pittsburgh, Pennsylvania, is a leading provider of aluminum sheet, plate and extrusions, as well as innovative architectural products, that advance the ground transportation, aerospace, industrial, packaging and building and construction markets.

For more information: www.arconic.com.

Dissemination of Company Information

Arconic intends to make future announcements regarding Company developments and financial performance through its website at www.arconic.com.

Forward-Looking Statements

This release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those containing such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning. All statements that reflect Arconic Corporation’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements. These statements reflect beliefs and assumptions that are based on Arconic’s perception of historical trends, current conditions and expected future developments, as well as other factors Arconic believes are appropriate in the circumstances. Forward-looking statements are not guarantees of future performance. Although Arconic Corporation believes that the expectations reflected in any forward-looking statements are based on reasonable assumptions, these expectations may not be attained and it is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of risks and uncertainties, many of which are beyond Arconic’s control. Such risks and uncertainties include, but are not limited to, the risk factors summarized in Arconic’s reports filed with the U.S. Securities and Exchange Commission (SEC). The statements in this release are made as of the date of this release, even if subsequently made available by Arconic on its website or otherwise. Arconic disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Investor Contact

Jason Secore

Shane Rourke

(412) 315-2984

[email protected]

Media Contact

Tracie Gliozzi

(412) 992-2525

[email protected]

KEYWORDS: Pennsylvania New York United States North America

INDUSTRY KEYWORDS: Aerospace Manufacturing Steel Packaging Engineering

MEDIA:

Logo
Logo
Posted on

Flux Power to Present at the LD Micro Main Event Conference on December 15 at 12 PM ET

Flux Power to Present at the LD Micro Main Event Conference on December 15 at 12 PM ET

VISTA, Calif.–(BUSINESS WIRE)–
Flux Power Holdings, Inc. (“Flux Power”) (NASDAQ: FLUX), a developer of advanced lithium-ion industrial batteries for commercial and industrial equipment, today announced that CEO Ron Dutt will present at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15 at 12:00 PM ET (9:00 AM PT).

“The 13th Annual LD Micro Main Event investor conference is a great venue for investors to learn about small, high-growth companies,” said Flux Power CEO, Ron Dutt. “I’m excited about this opportunity to share the Flux Power story and provide an update on our strategy and execution. Despite the COVID-19 pandemic, which has affected all aspects of the economy, we’ve made solid progress and look forward to continued momentum in 2021 and beyond.”

Register here.

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

“The time has finally come to do something different in the virtual conference world. Let’s see if we can pull off something that can be enjoyed by both executives and investors alike,” stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

View Flux Power’s profilehere.

About Flux Power Holdings, Inc. (www.fluxpower.com)

Flux Power designs, develops, manufactures, and sells advanced rechargeable lithium-ion energy storage solutions for lift trucks and other industrial equipment including airport ground support equipment (GSE), energy storage for solar applications, and industrial robotic applications. Flux Power’s LiFT Packs, including the proprietary battery management system (BMS), provide customers with a better performing, more environmentally friendly, and lower total cost alternative, in many instances, to traditional lead acid and propane-based solutions.

Flux, Flux Power, and associated logos are trademarks of Flux Power Holdings, Inc. All other third-party brands, products, trademarks, or registered marks are the property of and used to identify the products or services of their respective owners.

Follow us at:

Blog:

Flux Power Blog

News:

Flux Power News

Twitter:

@FLUXpwr

LinkedIn:

Flux Power

 

Flux Power Media & Investor Relations:

Justin Forbes

877-505-3589

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Hardware Other Manufacturing Manufacturing

MEDIA:

Logo
Logo
Posted on

H.I.G. Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing December 11, 2020

H.I.G. Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing December 11, 2020

MIAMI–(BUSINESS WIRE)–
H.I.G. Acquisition Corp. (NYSE: HIGA.U) (the “Company”) announced that, commencing December 11, 2020, holders of the units sold in the Company’s initial public offering of 36,394,500 units may elect to separately trade the Class A ordinary shares and warrants included in the units. Those units not separated will continue to trade on the New York Stock Exchange (“NYSE”) under the symbol “HIGA.U,” and the Class A ordinary shares and warrants that are separated will trade on the NYSE under the symbols “HIGA” and “HIGA WS,” respectively. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into Class A ordinary shares and warrants.

The units were initially offered by the Company in an underwritten offering. Credit Suisse Securities (USA) LLC served as lead book-running manager for the offering. Morgan Stanley & Co. LLC and BofA Securities served as book-running managers for the offering. A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission (the “SEC”) on October 20, 2020.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephes Drive, Morrisville, North Carolina 27560, Telephone: 1-800-221-1037, Email: [email protected]; Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014, email: [email protected]; or BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-001; Email: dg.prospectus—[email protected].

About H.I.G. Acquisition Corp.

H.I.G. Acquisition Corp is a newly incorporated blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is sponsored by H.I.G. Acquisition Advisors, LLC, an affiliate of H.I.G. Capital, LLC (“HIG”). H.I.G. Acquisition Corp., led by its Chief Executive Officer Brian Schwartz, a Co-President of HIG, and its President Rob Wolfson, an Executive Managing Director of HIG, will not be limited to a particular industry or geographic region in its identification and acquisition of a target company. The Company plans to leverage HIG’s deal-sourcing network, which has investment experience in the healthcare, technology, media and telecommunications, services, industrial, consumer and other sectors.

Forward-Looking Statements

This press release may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus relating to the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Timur Akazhanov

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Posted on

InfuSystem to Announce Full Year 2021 Guidance on Tuesday, December 15, 2020

Conference Call to be held 9:00 a.m. Eastern Time

ROCHESTER HILLS, Michigan, Dec. 10, 2020 (GLOBE NEWSWIRE) — December 10, 2020 – InfuSystem Holdings, Inc. (NYSE American: INFU), (“InfuSystem” or the “Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that it will issue full year 2021 annual financial guidance on Tuesday, December 15, 2020, before the market opens.

The Company will also conduct a conference call for all interested investors on Tuesday, December 15, 2020, at 9:00 a.m. Eastern Time to discuss its full year 2021 guidance and business developments.

To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/.  A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10150400, through December 22, 2020.


About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The lead platform is Integrated Therapy Services (“ITS”), providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The ITS segment is comprised of Oncology, Pain Management, and Wound Therapy businesses. The second platform, Durable Medical Equipment Services (“DME Services”), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payor clients. The DME Services segment is comprised of direct payor rentals, pump and consumable sales, and biomedical services and repair.  Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada.

# # #



CONTACT: 
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
602-889-9700

Posted on

Amplify Energy Announces Secondary Public Offering of Common Stock for Selling Stockholders

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) — Amplify Energy Corp. (NYSE: AMPY) (“Amplify”) today announced the commencement of an underwritten public offering of 8,548,485 shares of its common stock by certain of its stockholders which are affiliates of Fir Tree Capital Management L.P.

Amplify will not sell any shares of its common stock in the offering and will not receive any proceeds therefrom.

Roth Capital Partners is acting as the Sole Manager for the offering.

This offering is being made pursuant to effective shelf registration statements (File No. 333-233677, effective October 11, 2019, and 333-215602, effective May 1, 2018) and prospectuses filed by Amplify with the Securities and Exchange Commission (“SEC”). The offering of these securities will be made only by means of a prospectus and prospectus supplement. A preliminary prospectus supplement has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from Roth Capital Partners, Attention: Equity Capital Markets, 888 San Clemente Drive, Newport Beach, California 92660, by telephone at (800) 678-9147 or e-mail at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful without registration or qualification under the securities laws of any such state or jurisdiction.

About Amplify Energy

Amplify Energy Corp. is an independent oil and natural gas company engaged in the acquisition, development, exploration and production of oil and natural gas properties. Amplify’s operations are focused in Oklahoma, the Rockies, offshore California, East Texas / North Louisiana and South Texas. For more information, visit www.amplifyenergy.com.

Cautionary Statement Concerning Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that Amplify expects, believes or anticipates will or may occur in the future are forward-looking statements. Terminology such as “will,” “would,” “should,” “could,” “expect,” “anticipate,” “plan,” “project,” “intend,” “estimate,” “believe,” “target,” “continue,” “potential,” the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Amplify believes that these statements are based on reasonable assumptions, but such assumptions may prove to be inaccurate. Such statements are also subject to a number of risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Amplify, which may cause Amplify’s actual results to differ materially from those implied or expressed by the forward-looking statements. Please read Amplify’s filings with the Securities and Exchange Commission, including “Risk Factors” in its Annual Report on Form 10-K, and if applicable, its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other public filings and press releases for a discussion of risks and uncertainties that could cause actual results to differ from those in such forward-looking statements. All forward-looking statements speak only as of the date of this press release. All forward-looking statements in this press release are qualified in their entirety by these cautionary statements. Amplify undertakes no obligation and does not intend to update or revise any forward-looking statements, whether as a result of new information, future results or otherwise.

In
vestor Relations Contacts

Martyn Willsher – Interim CEO & CFO
(832) 219-9047
[email protected]

Jason McGlynn – VP, Business Development
(832) 219-9055
[email protected]



Posted on

Brunswick Corporation Awarded Community Support Initiative Award during 2020 Boat Builder Awards

METTAWA, Ill., Dec. 10, 2020 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) was named one of two companies to win the Community Support Initiative Boat Builders Award today during the 2020 virtual METSTRADE Show.

The Community Support Initiative represents a new 2020 category established in response to the COVID-19 crisis. Brunswick and its employees were recognized for demonstrating great social awareness by channeling resources, expertise and manufacturing capabilities to aid the communities in which they live and work as well as providing COVID-19 crisis support.

“We are honored to win the Community Support Initiative Award and thank the judges for recognizing our efforts to prioritize the health and safety of our employees and their families above all else,” said Dave Foulkes, Brunswick Corporation CEO.   “We understand the important role we play, not just as the leader in the marine industry, but as a leader in our global communities. It is incumbent upon us to make a difference and do our part to mitigate the impacts of COVID-19.”

Brunswick has been praised throughout the year for its commitment to helping workers on the frontlines fight against COVID-19.

“Brunswick Corporation is well deserving of our Community Support Initiative award in 2020 as they did a fantastic job of stepping up to support their communities once COVID-19 hit,” said Ed Slack, IBI Editor-in-Chief.  “Given the unique times we find ourselves in, we felt this year’s Awards was the perfect opportunity to highlight the heroic work undertaken by many of our boatbuilders and their employees in keeping the industry moving forward in these uncertain times.  From making masks, to donating time and money as well as ensuring that the health and safety of their employees remained their top priority, Brunswick should be commended for their efforts.”

The Boat Builder Awards were initiated by METSTRADE and International Boat Industry magazine (IBI) in 2015 to recognize the business achievements of leisure boat builders, as well as the teams and individuals that make them successful. It has since then grown to become a prestigious and widely recognized awards program.

About Brunswick

Headquartered in Mettawa, Ill., Brunswick Corporation’s leading consumer brands include Mercury Marine outboard engines; Mercury MerCruiser sterndrive and inboard packages; Mercury global parts and accessories including propellers and SmartCraft electronics; Power Products Integrated Solutions; MotorGuide trolling motors; Attwood, Garelick, and Whale marine parts; Land ’N’ Sea, BLA, Payne’s Marine, Kellogg Marine, and Lankhorst Taselaar marine parts distribution; Mercury and Quicksilver parts and oils; Bayliner, Boston Whaler, Crestliner, Cypress Cay, Harris, Lowe, Lund, Princecraft, Quicksilver, Rayglass, Sea Ray, Thunder Jet and Uttern boats; Boating Services Network, Freedom Boat Club, NAUTIC-ON. For more information, visit https://www.brunswick.com.

Attachment 



Lee Gordon
Vice President – Brunswick Global Communications & Public Relations
Brunswick Office: 847-735-4003
Mercury Office: 920-924-1808
Cell: 904-860-8848
[email protected]

Posted on

ERYTECH to Present at the JMP Securities Hematology Summit

LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced todaythat CEO, Gil Beyen, will present at the JMP Securities Hematology Summit Tuesday December 15th at 1:30pm EST /06:30pm GMT /7:30pm CET. The format will be a “fireside chat” discussion hosted by  JMP Securities’ Reni Benjamin.

The event will be held virtually, with all corporate and institutional participants joining remotely.

A webcast of the event will be available by clicking here and will be accessible via ERYTECH’s website at http://www.erytech.com/investors/webcast/

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in acute lymphoblastic leukemia was recently completed in the Nordic countries of Europe. Eryaspase is not approved in any country.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable,
EnterNext
PEA-PME 150 and Next Biotech indexes.        
For more information, please visit www.erytech.com        

Forward-looking information

This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans of eryaspase; the potential indications for and benefits of eryaspase; statements relating to the TRYbeCA-1 clinical trial, including the timeline for patient enrollment as well as expected timing of the availability of results and interim superiority analysis; potential impacts on the Company’s clinical trials, including TRYbeCA-1 clinical trial, due to the coronavirus (COVID-19) pandemic such as delays in regulatory review, manufacturing and supply chain interruptions; and the overall impact of the COVID-19 pandemic on the global healthcare system as well as the Company’s business, financial condition and results of operations. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH’s control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company’s Securities and Exchange Commission (SEC) filings and reports, including in the Company’s 2019 Document d’Enregistrement Universel filed with the AMF on March 18, 2020 and in the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2020 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company’s business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company’s business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic. The pandemic could have a material adverse impact on the Company’s business, operations and financial results for an extended period of time.

CONTACTS

ERYTECH                     
Eric Soyer
CFO & COO		 LifeSci Advisors, LLC

Investor Relations
Corey Davis, Ph.D.

 NewCap

Mathilde Bohin /

Louis-Victor Delouvrier

Investor relations
Nicolas Merigeau
Media relations

+33 4 78 74 44 38
[email protected] 
+1 (212) 915 – 2577
[email protected]
+33 1 44 71 94 94
[email protected]

PDF available at: http://ml.globenewswire.com/Resource/Download/25324f5e-902d-4520-a88b-f86633ed3148



Posted on

Neovasc Announces Closing of US$6.1 Million Registered Direct Offering Priced At-the-Market

VANCOUVER and MINNEAPOLIS, Dec. 10, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under the Nasdaq Capital Market (the “Nasdaq”) rules of an aggregate of 6,230,803 common shares at a price of US$0.9801 per common share.  Aggregate gross proceeds to the Company were approximately US$6.1 million, before deducting placement agent’s fees and estimated expenses of the Offering payable by the Company. 

H.C. Wainwright & Co. acted as the exclusive placement agent for the Offering.

Each common share was sold, in a concurrent private placement in the United States, with one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to acquire one common share of the Company (each, a “Warrant Share”) at an exercise price of US$0.856 per share at any time prior to the date which is five and one half years following the date of issuance.

Neovasc intends to use the net proceeds from the Offering for the development and commercialization of the Neovasc Reducer™ (the “Reducer”), development of the Tiara™ (the “Tiara”) and general corporate and working capital purposes.

The common shares (but not the Warrants or the Warrant Shares) were offered pursuant to a “shelf” registration statement on Form F-3 (File No. 333-245385) previously filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2020 and declared effective by the SEC on September 14, 2020. A prospectus supplement to the Company’s base shelf prospectus dated August 12, 2020 qualifying the distribution of the common shares and Warrants was also filed with the provincial securities regulatory authorities in British Columbia, Alberta, Saskatchewan, Manitoba and Ontario. Neovasc offered and sold the common shares in the United States only. No securities were offered or sold to Canadian purchasers.

A final prospectus supplement and accompanying prospectus relating to the Offering was filed with the SEC and is available for free on the SEC’s website at www.sec.gov and is also available on the Company’s profile on the SEDAR website at www.sedar.com. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the Offering may be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, or by telephone: (646) 975-6996 or by e-mail: [email protected].

The Warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the Warrant Shares, have not been registered under the Act, or applicable state securities laws. Accordingly, the Warrants and Warrant Shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

For the purposes of the final approval of the Toronto Stock Exchange (the “TSX”), the Company has relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq.

This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.


Investors


Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
[email protected]


Media


Sean Leous
Westwicke/ICR
Phone: +1.646.677.1839
[email protected]

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact.  When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the use of proceeds, the expected impact on Reducer revenue generation during the fourth quarter, the Company’s ability to build on progress and optimizing the value of its devices, the likelihood of approval under the FDA’s decision on the PMA, the expansion of its product range, prospects for regulatory approvals and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, market and other conditions as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F and in the Management’s Discussion and Analysis for the three and nine months ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Posted on

iBio Announces Closing of its Public Offering of Common Stock

BRYAN, Texas, Dec. 10, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the closing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. In addition, iBio has granted the underwriter a 30-day option to purchase up to approximately 4.4 million additional shares of its common stock.

Cantor Fitzgerald & Co. was the sole book-running manager for the offering. Roth Capital Partners acted as financial advisor to iBio.

iBio anticipates using the net proceeds from the offering to accelerate development of its biotherapeutic and vaccine candidates, in-licensing of biopharmaceutical assets, including, but not limited to, those in oncology, fibrotic, and infectious diseases, and working capital needs and for other general corporate purposes, including acquisitions and investments in other businesses.

A shelf registration relating to the shares of common stock offered in the public offering described above was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC on December 7, 2020. A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying base prospectus relating to this offering may also be obtained by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with the Glycaneering Development Service™ for engineering high-performance recombinant glycoproteins.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the anticipated use of proceeds. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including its infectious disease vaccines, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended June 30, 2020 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Form 10-Q and Form 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
[email protected]



Posted on

PFD, PFO, FFC, FLC and DFP Announce December and January Dividends

PFD, PFO, FFC, FLC and DFP Announce December and January Dividends

PASADENA, Calif.–(BUSINESS WIRE)–
The Boards of Directors of Flaherty & Crumrine Preferred and Income Fund Incorporated (NYSE:PFD), Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated (NYSE:PFO), Flaherty & Crumrine Preferred and Income Securities Fund Incorporated (NYSE:FFC), Flaherty & Crumrine Total Return Fund Incorporated (NYSE:FLC) and Flaherty & Crumrine Dynamic Preferred and Income Fund Incorporated (NYSE:DFP) today announced that they have declared per share dividends for December 2020 and January 2021. In addition, PFO announced a special year-end dividend to be paid this month. These dividends are detailed below:

 

 

Special Year-End

 

December

 

January

PFD

 

—

 

$0.0860

 

$0.0860

PFO

 

$0.02

 

$0.0680

 

$0.0680

FFC

 

—

 

$0.1290

 

$0.1290

FLC

 

—

 

$0.1320

 

$0.1320

DFP

 

—

 

$0.1650

 

$0.1650

 

 

 

 

 

 

 

Payment Date

 

December 31, 2020

 

December 31, 2020

 

January 29, 2021

Record Date

 

December 23, 2020

 

December 23, 2020

 

January 22, 2021

Ex-Dividend Date

 

December 22, 2020

 

December 22, 2020

 

January 21, 2021

Each fund’s fiscal year ended on November 30, 2020. The tax breakdown of all 2020 distributions will be available early in 2021, but at this point each fund anticipates that each of its dividends detailed above, including the special year-end dividend, will consist of net investment income and not capital gains or return of capital.

Website: www.preferredincome.com

Past performance is not indicative of future performance. An investor should consider the fund’s investment objective, risks, charges and expenses carefully before investing.

To the extent any portion of the distribution is estimated to be sourced from something other than income, such as return of capital, the source would be disclosed on a Section 19(a)-1 letter located under the “SEC Filings and News” section of the funds’ website, www.preferredincome.com. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a fund’s investment performance during the remainder of its fiscal year and may be subject to change based on tax regulations. A distribution rate that is largely comprised of sources other than income may not be reflective of a fund’s performance.

PFD, PFO and FFC invest primarily in preferred and other-income producing securities with an investment objective of high current income consistent with preservation of capital. FLC invests primarily in preferred and other income-producing securities with a primary investment objective of high current income and a secondary objective of capital appreciation. DFP invests primarily in preferred and other income-producing securities with an investment objective of total return, with an emphasis on high current income. PFD, PFO, FFC, FLC and DFP are managed by Flaherty & Crumrine Incorporated, an independent investment adviser which was founded in 1983 to specialize in the management of portfolios of preferred and related income-producing securities.

Flaherty & Crumrine Incorporated

Chad Conwell, 626-795-7300

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA: